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UNITED STATES DISTRICT COURT
MIDDLE DISTRICT OF FLORIDA
TAMPA DIVISION
FEDERAL TRADE COMMISSION,
Plaintiff,
v.

Case No: 8:15-cv-2231-T-35TBM

ROCA LABS, INC., a corporation,
ROCA LABS NUTRACEUTICAL USA,
INC., a corporation, DON JURAVIN,
individually, DON JURAVIN, as an
officer of Roca Labs, Inc. and Roca
Labs Nutraceutical USA, Inc. Must
Cure Obesity, Co and Juravin, Inc.,
GEORGE C. WHITING, individually,
GEORGE C. WHITING, as an officer of
Roca Labs, Inc. and Roca Labs
Nutraceutical USA, Inc. and Zero
Calorie Labs, Inc., MUST CURE
OBESITY, CO., a corporation,
JURAVIN, INCORPORATED, a
corporation, and ZERO CALORIE
LABS, INC., a corporation,
Defendants.
/
ORDER
THIS CAUSE comes before the Court for consideration of Plaintiff’s Amended
Motion for Summary Judgment Against All Defendants (Dkt. 210); Defendants’ response
in opposition thereto (Dkt. 221); Plaintiff’s reply (Dkt. 228); Defendants’ [Amended] Motion
for Partial Summary Judgment as to Count Three of the Amended Complaint (Dkt. 212);
and Plaintiff’s response in opposition thereto. (Dkt. 216) Upon consideration of all
relevant filings, case law, and being otherwise fully advised, the Court GRANTS Plaintiff’s
Amended Motion for Summary Judgment (Dkt. 210) and DENIES Defendants’ [Amended]
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Motion for Partial Summary Judgment as to Count Three of the Amended Complaint.
(Dkt. 212)
I.

BACKGROUND
A.

The Plaintiff

The Federal Trade Commission (“FTC” or “Plaintiff”) is an independent agency of
the United States Government established by statute. 15 U.S.C. §§ 41–58. The FTC
has the power to enforce Section 5(a) of the FTC Act, 15 U.S.C. § 45(a), which prohibits
unfair or deceptive acts or practices in or affecting commerce, and Section 12 of the FTC
Act, 15 U.S.C. §§ 52, 55, which prohibits false advertisements for food, drugs, devices,
services, or cosmetics in or affecting commerce.
B.

The Defendants

There are seven named defendants in this action, including five corporate
defendants. Defendants Roca Labs, Inc. (“RLI”), Roca Labs Nutraceutical USA, Inc.
(“RLNU”), Must Cure Obesity, Co. (“MCO”), Juravin, Incorporated (“JI”), and Zero Calorie
Labs, Inc. (“ZCL”) (collectively, “Corporate Defendants”) are Florida entities. (Dkt. 48)
Defendant Don Juravin (“Juravin”) owns MCO and JI and has been an officer of RLI and
RLNU. (Dkts. 210, 219) Defendant George Whiting (“Whiting”) owns and has been an
officer of RLI, RLNU, and ZCL. (Id.) The FTC alleges that the Corporate Defendants
operated a common enterprise to sell Roca Labs products through deceptive and unfair
practices. (Dkt. 48) It also alleges that Defendants Juravin and Whiting “formulated,
directed, controlled, had the authority to control, or participated in the acts and practices
of RLI, RLNU, MCO, JI, and ZCL.” (Id. at 6)
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C.

Factual Background

On September 24, 2015, the FTC filed this action, alleging that Defendants
engaged in acts and practices that violated Sections 5 and 12 of the Federal Trade
Commission Act, 15 U.S.C. §§ 45, 52, in connection with the advertising and sale of
weight-loss products and the use of contractual provisions prohibiting purchasers from
providing negative commentary.
temporary restraining order.

(Dkt. 1)

(Id.)

At the same time, the FTC moved for a

On September 29, 2015, the Court entered a

Stipulated Temporary Restraining Order (“TRO”) agreed to by the FTC and Defendants
Juravin, Whiting, RLI, and RLNU (collectively, “the Four Enjoined Defendants”). (Dkt.
13) The Parties stipulated to preserve their assets while the case remained pending.
(Dkt. 13-1) On October 29, 2015, the Court issued a Preliminary Injunction, imposing
various restraints against the Four Enjoined Defendants. (Dkt. 38)
On February 19, 2016, the FTC filed an Amended Complaint for Permanent
Injunction and Other Equitable Relief (“Complaint”). (Dkt. 48) On September 13, 2016,
the Court issued a Stipulated Preliminary Injunction Freezing Assets with Other Equitable
Relief applicable to all Defendants, except Defendant Whiting. (Dkt. 90)
In the Complaint, the FTC alleges the following: Since at least 2009, Defendants
have advertised, marketed, sold, and distributed weight-loss products, including Roca
Labs Formula (“Formula”) and Roca Labs Anti-Cravings (“Anti-Cravings”). (Dkt. 48 ¶ 15)
Defendants’ revenues from the sale of these products since 2010 were at least $20
million. (Id. ¶ 18) The products were sold in powder form that consumers could mix
with water or other liquid to drink. (Id. ¶ 15) Defendants marketed the weight-loss
products as a safe and cost-effective alternative to gastric bypass surgery to combat
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obesity and achieve substantial weight loss. (Id.) Defendants have used the terms
“Gastric Bypass No Surgery” or “Gastric Bypass alternative” in the promotions of their
products. (Id. ¶¶ 19, 23) Defendants also have used illustrations, such as the one
below, to depict how the formula is used.

(Id. at 10; Dkt. 2 at 2, 5) Defendants also stated that the products are safe for children
as young as six years old, although they recommended parental supervision and
consultation with a doctor. (Dkt. 48 at 13 ¶ 27h)
Defendants promoted their products in a variety of ways, such as through their
websites, including RocaLabs.com and Mini-Gastric-Bypass.me (“Roca Labs Websites”),
and by using online advertisements to direct consumers to the Roca Labs Websites. (Id.
¶¶ 19, 22–24) In videos on the Roca Labs Websites and Defendants’ social media
pages, Defendants also made representations about the Roca Labs products, such as:
What is the Formula? Roca Labs’ Formula is a medical innovation that
creates a natural gastric bypass effect in the stomach. It’s based on healthy
fibers, and it’s classified as a food supplement. Just mix with water, take it
each morning, and it immediately expands to physically fill your stomach.
For the next 10 to 16 hours, only 20% of your stomach will be available for
food intake. Your new, small stomach will force you to eat 50% less from
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day one.
(Id. ¶ 28a) The Roca Labs Websites also included links to documents, such as “Letter
to Your Doctor V1-Aug12,” purportedly written by a doctor or other medical professional,
that describe the benefits of Roca Labs products and summarize scientific literature
regarding those benefits. (Id. ¶¶ 30–31) At times, the Letter to Your Doctor segment was
attributed to “Dr. Ross Finesmith, Director of Medical Team” or “Ross Finesmith, M.D.
Medical Consultant.” (Id. ¶ 31) Finesmith made statements regarding his experience
with the Formula and the products’ efficacy.

(Id.)

The Roca Labs Websites used

medical images, such as the Caduceus symbol and people dressed in white lab coats,
and medical terminology, including “medical team,” “medical innovation,” and “research
center.” (Id. ¶ 33) In fine print, as part of the “Terms and Conditions” section of the
RocaLabs.com website, Defendants stated that “[n]o clinical study has been performed
on this product.” (Id. ¶ 32) The Roca Labs Websites included testimonials and thirdparty reviews as promotional material. (Id. ¶ 34) Defendants solicited the testimonials,
called “Success Videos,” by offering to pay customers who purchased the Roca Labs
products up to $1,000.00 upon meeting certain conditions, such as achieving a certain
interim weight loss goal, providing an inspirational and convincing success story, and
demonstrating that the weight loss is evident in “before & after” images. (Id. ¶¶ 35–36)
Defendants did not disclose that the people in the videos were paid or received offers of
pay for their testimonials. (Id. ¶ 38) Defendants also did not disclose that they, or
someone working on their behalf, posted testimonials or other information about Roca
Labs products on third-party blogs or websites. (Id. ¶ 39) Defendants failed to disclose
that they operated Gastricbypass.me, a website that discusses bariatric surgery and
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features a “Surgical Alternatives” page devoted to positive commentary on Roca Labs
products and which also sells the Roca Labs products. (Id. ¶ 40) Defendants did not
disclose that Gastricbypass.me is affiliated with RLI or RLNU. (Id.)
Defendants advertised that the basic package of Roca Labs products costs
$480.00 with “valid health insurance.” (Id. ¶¶ 18, 41) Without insurance, the basic
package costs $640.00. 1

(Id.)

The basic package included a three to four-month

supply of the Formula and an approximate three-month supply of the Anti-Cravings
product.

(Id. ¶ 41)

Consumers who desired to purchase the Roca Labs products

through the Roca Labs Website were required to enter their information through the
“Qualify & Order” pages, which featured videos about the qualification process and stated
that the information consumers provided would be kept confidential and would not be
shared. (Id. ¶ 42) The prospective customers were required to provide complete a
“Questionnaire” or “Health Application,” which included questions about cholesterol, high
blood pressure, diabetes, digestion, and other health conditions. (Id. ¶ 43) The Health
Application also asked consumers about psychological or emotional issues relating to
weight, past weight-loss failures, depression, and binge eating. (Id.)
When the products were shipped to customers, Defendants included in the
package, among other items and documents, a “Summary” document that stated the
customers’ information would not be shared with anyone. (Id. ¶ 45) A “Thanks for
purchasing” document, also included in the shipped packaging, warned that there are no
returns or refunds and that those who cancel or dispute installment payments may face
legal action and $3,500 in charges. (Id.) The “Roca Labs Procedure Rules & Diet”

1 There is nothing in the record to indicate that Defendants ever billed health insurance companies.
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insert listed the rules: eat between 11 a.m. and 8 p.m. only or any nine-hour interval; eat
a healthy, 100-calorie snack before 11 a.m.; and eat vegetables or occasionally lowcalorie popcorn as a snack between 8 p.m. and 10 p.m. (Id. ¶ 46) Customers also were
advised that “[t]o maintain the gastric bypass effect, [they should] drink at least six ½ liter
bottles of water a day,” exercise at least five times a week, and document their success
by video weekly.

(Id.)

The “Roca Labs Procedure Rules & Diet” insert also was

available online at Roca Labs Websites to prospective customers. (Id.)
Since at least September 2012, Defendants have included a non-disparagement
clause, also known as a “gag clause,” in the Terms and Conditions that prohibited
customers from publishing disparaging comments about Roca Labs products. (Id. ¶¶
47–53)

The Terms and Conditions also indicated that the purchase price was

“conditional,” “discounted,” or “subsidized” in exchange for the customer’s agreement to
the gag clause and other provisions in the Terms and Conditions. (Id. ¶ 51) The Terms
and Conditions stated that the purchaser agrees to pay the full price of the product,
$1,580.00, if the purchaser breached the gag clause. (Id. ¶¶ 49, 51)

In the September

2012 version, the Terms and Conditions stated that customers would have to compensate
Defendants $100,000 for talking “badly about the Formula.” (Id. ¶ 52; Dkt. 2-1 at 56) In
the August 2014 version of the Terms and Conditions, customers were subject to being
sued for an injunction and being billed $3,500.00 for legal fees and court costs for
publishing any negative comments about the Defendants’ products, services, or
employees. (Dkt. 48 ¶ 52; Dkt. 2-1 at 26) That version also provided that Defendants
could force purchasers to sign a notarized affidavit stating that the disparaging remarks
were incorrect, contained factually incorrect material, and breached the Terms and
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Conditions. (Dkt. 48 ¶ 52; Dkt. 2-1 at 26–27) These alleged acts form the basis of the
FTC’s seven-count Complaint.
In Count I, the FTC asserts deceptive weight-loss claims. The FTC alleges that
Defendants have made deceptive weight-loss claims by representing that:
a. Use of Defendants’ products, including Roca Labs Formula and Roca
Labs Anti-Cravings, enables the user to reduce food intake by fifty percent
and to lose substantial amounts of weight quickly, including as much as 21
pounds in one month, and as much as 100 pounds in seven to ten months;
b. Ninety percent of users of Defendants’ products, including Roca Labs
Formula and Roca Labs Anti-Cravings, will lose substantial amounts of
weight;
c. Defendants’ products, including Roca Labs Formula and Roca Labs AntiCravings, are comparable or superior to bariatric surgery in providing weight
loss benefits; and
d. Defendants’ products, including Roca Labs Formula and Roca Labs AntiCravings, are safe and effective for weight loss in children as young as six
years old.
(Id. ¶ 61) The FTC alleges that these representations were false or misleading or were
not substantiated at the time they were made. The representations, the FTC contends,
constitute deceptive acts or practices and false advertisement, in or affecting commerce,
in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. (Id. ¶¶
62–63)
In Count II, the FTC asserts a false establishment claim. Plaintiff alleges that
Defendants’ representation that the use of the products, including the Formula and AntiCravings, is scientifically proven to have a ninety percent success rate in forcing users to
eat half their usual food intake and cause substantial weight loss is false or misleading.
(Id. ¶ 64) The FTC also alleges that this representation constitutes a deceptive act or
practice and a false advertisement, in or affecting commerce, in violation of 5(a) and 12
of the FTC Act, 15 U.S.C. §§ 45(a) and 52. (Id. ¶ 66)
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In Count III, the FTC contends that Defendants’ use of the non-disparagement
provision, or gag clause, in the sale of the products constitutes unfair acts or practices in
violation of Section 5 of the FTC Act, 15 U.S.C. §§ 45(a) and (n). (Id. ¶ 69)
In Count IV, the FTC alleges that Defendants misrepresented Gastricbypass.me
as an independent, objective resource for information regarding bariatric surgery,
alternatives to bariatric surgery for weight loss, and Roca Labs products. (Id. ¶ 70) The
FTC alleges that this representation was false or misleading and constitutes a deceptive
act or practice and a false advertisement, in or affecting commerce, in violation of
Sections 5(a) of the FTC Act, 15 U.S.C. § 45(a). (Id. ¶ 72)
In Count V, the FTC alleges that Defendants failed to disclose that people who
appeared in their advertising providing testimonials were paid or received offers of pay.
(Id. ¶ 74) Plaintiff also alleges that Defendants failed to disclose that Defendants own
Gastricbypass.me and that they sell the Formula and Anti Cravings products. (Id.) The
failure to disclose this information, the FTC argues, is a deceptive act or practice and a
false advertisement, in or affecting commerce, in violation of Sections 5(a) of the FTC
Act, 15 U.S.C. § 45(a). (Id. ¶ 75)
In Count VI, the FTC asserts a deceptive privacy claim. The FTC contends that
Defendants’ representation that they do not disclose consumers’ information, including
health information, and keep consumers’ information confidential is false or misleading.
(Id. ¶¶ 76, 78) Such a representation, according to the FTC, constitutes a deceptive act
or practice, in or affecting commerce, in violation of Section 5(a) of the FTC Act, 15 U.S.C.
§ 45(a). (Id. ¶ 78)
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In Count VII, the FTC asserts a deceptive discount claim. The FTC challenges
Defendants’ representation that purchasers agreed to pay the difference between the “full
price” and the purported “discount” price if they post negative comments or reviews about
Defendants, their products, or employees. This representation, the FTC contends, is
false or misleading and constitutes a deceptive act or practice, in or affecting commerce,
in violation of Section 5(a) of the FTC Act, 15 U.S.C. § 45(a). (Id. ¶¶ 79, 81)
On April 26, 2018, the FTC filed an amended motion for summary judgment on all
claims. (Dkt. 210) Defendants moved for partial summary judgment as to Count III.
(Dkt. 212)
II.

LEGAL STANDARD
Summary judgment is appropriate when the movant can show there is no genuine

issue of material fact and that the movant is entitled to judgment as a matter of law.
Fennell v. Gilstrap, 559 F.3d 1212, 1216 (11th Cir. 2009) (citing Welding Servs., Inc. v.
Forman, 509 F.3d 1351, 1356 (11th Cir. 2007)). Which facts are material depends on
the substantive law applicable to the case. Anderson v. Liberty Lobby, Inc., 477 U.S.
242, 248 (1986). The moving party bears the burden of showing that no genuine issue
of material fact exists. Clark v. Coats & Clark, Inc., 929 F.2d 604, 608 (11th Cir. 1991).
Evidence is reviewed in the light most favorable to the non-moving party. Fennell,
559 F.3d at 1216 (citing Welding Servs., Inc., 509 F.3d at 1356).

A moving party

discharges its burden on a motion for summary judgment by showing or pointing out to
the Court that there is an absence of evidence to support the non-moving party’s case.
Denney v. City of Albany, 247 F.3d 1172, 1181 (11th Cir. 2001) (citation omitted).
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When a moving party has discharged its burden, the non-moving party must then
designate specific facts (by its own affidavits, depositions, answers to interrogatories, or
admissions on file) that demonstrate there is a genuine issue for trial. Porter v. Ray, 461
F.3d 1315, 1320–1321 (11th Cir. 2006) (citation omitted). The party opposing a motion
for summary judgment must rely on more than conclusory statements or allegations
unsupported by facts. Evers v. Gen. Motors Corp., 770 F.2d 984, 986 (11th Cir. 1985)
(“conclusory allegations without specific supporting facts have no probative value.”). “If
a party fails to properly support an assertion of fact or fails to properly address another
party’s assertion of fact . . . the court may grant summary judgment if the motion and
supporting materials . . . show that the movant is entitled to it.” Fed. R. Civ. P. 56(e).
“The standard of review for cross-motions for summary judgment does not differ
from the standard applied when only one party files a motion, but simply requires a
determination of whether either of the parties deserves judgment as a matter of law on
the facts that are not disputed.” S. Pilot Ins. Co. v. CECS, Inc., 52 F. Supp. 3d 1240,
1242–43 (N.D. Ga. 2014) (citing Am. Bankers Ins. Group v. United States, 408 F.3d 1328,
1331 (11th Cir. 2005)). “Cross-motions may, however, be probative of the absence of a
factual dispute where they reflect general agreement by the parties as to the controlling
legal theories and material facts.” Id. at 1243 (citing United States v. Oakley, 744 F.2d
1553, 1555–56 (11th Cir.1984)).
III.

DISCUSSION
A.

Deceptive and False Advertisement (Counts I, II, IV, V, VI, VII)

Section 5(a) of the FTC Act prohibits unfair or deceptive acts or practices in or
affecting commerce.

15 U.S.C. § 45(a).
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dissemination of false advertisements for food, drugs, devices, services, or cosmetics in
or affecting commerce.

15 U.S.C. §§ 52, 55.

The dissemination of such false

advertisement is an unfair or deceptive practice as outlined in Section 5(a). 15 U.S.C. §
52(b). “Thus, a violation of Section 12, dissemination of false advertising, constitutes a
violation of Section 5(a).” FTC v. Nat’l Urological Group, Inc., 645 F. Supp. 2d 1167,
1188 (N.D. Ga. 2008), aff'd, 356 F. App’x 358 (11th Cir. 2009). Under the statute, a
“false advertisement” is “an advertisement, other than labeling, which is misleading in a
material respect.” 15 U.S.C. § 55(a)(1).
To demonstrate liability for unfair and deceptive commercial practices under
Section 5 or Section 12 of the FTC Act, the plaintiff must establish that “(1) there was a
representation; (2) the representation was likely to mislead customers acting reasonably
under the circumstances, and (3) the representation was material.” FTC v. Tashman,
318 F.3d 1273, 1277 (11th Cir. 2003) (citations omitted); 15 U.S.C. § 45.
Under this standard, courts first evaluate whether the advertisement made the
purported claims.

Nat’l Urological Group, Inc., 645 F. Supp. 2d at 1189.

The

determination is made by evaluating either the terms of the advertisements or “evidence
of what consumers interpreted the advertisement to convey.” Id. To determine the
meaning and representations of an advertisement, the court must consider the overall net
impression of the advertisement and whether reasonable consumers would interpret a
particular message. Id.
Under the second element of the standard, the FTC may establish that the
representation was likely to mislead customers under a “falsity theory” or a “reasonable
basis theory.” Id. at 1190.

In other words, the FTC may demonstrate (a) that the
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message conveyed by the advertisement was false or (b) that “the advertiser lacked a
reasonable basis—or adequate substantiation—for asserting that the message was true.”
Id.
Under the third prong, the FTC may demonstrate that the challenged
representation was material in several ways. A representation is material if a reasonable
prospective buyer is likely to rely upon it. FTC v. Washington Data Resources, 856 F.
Supp. 2d 1247, 1272 (M.D. Fla. 2012), aff’d sub nom. FTC v. Washington Data
Resources, Inc., 704 F.3d 1323 (11th Cir. 2013). Additionally, an express claim, an
intentionally-implied claim made by seller, and claims “that significantly involve health,
safety, or other areas with which reasonable consumers would be concerned” are
presumed material.

Kraft Inc. v. FTC, 970 F.2d 311, 322 (7th Cir. 1992) (citation

omitted); FTC v. Transnet Wireless Corp., 506 F. Supp. 2d 1247, 1266, 1267 (S.D. Fla.
2007).
1.

Defendants’ Weight-Loss Claims (Counts I, II)

The FTC alleges that Defendants’ five weight-loss claims, discussed above, are
false and deceptive. (Dkt. 210 at 26–27) In their response, Defendants raise no dispute
as to the existence of the representations or the materiality. (Dkt. 221) Thus, the Court
focuses its analysis of the alleged deceptive misrepresentations on the second element
of the three-part standard: whether consumers were likely to be misled by the claims in
the advertisements. For the reasons that follow, the Court finds that the FTC is entitled
to summary judgment on Counts I and II.
The FTC contends that Defendants’ claims are deceptive for two reasons: (1) the
claims are false, and (2) Defendants had no reasonable basis, or adequate
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substantiation, for their claims. (Dkt. 210 at 40–41) See Nat’l Urological Group, Inc., 645
F. Supp. 2d at 1190; FTC v. Pantron I Corp., 33 F.3d 1088, 1096 (9th Cir. 1994) (claim
may be deemed deceptive if the advertiser had no reasonable basis to assert the claims
as true or if the claim is demonstrably false).
The FTC has established that Defendants’ claims are false in that they were
material and likely to mislead consumers.

As discussed above, Defendants made

express claims regarding weight loss. Those express claims, which significantly involve
health, are inherently material. See Kraft, 970 F.2d at 322. Defendants disseminated
their claims online—through the Roca Labs Websites and online advertisements—to
direct consumers to the Roca Labs Websites to purchase the products.

The ads

intentionally contained medical images and terminology to bolster the credibility of
Defendants’ claims and induce customers to believe that the claims were scientifically
validated by the medical community. Thus, the Court concludes that the claims were
likely to mislead consumers acting reasonably under the circumstances.
The FTC also has established that Defendants had no reasonable basis to assert
the claims because they lack competent and reliable scientific evidence. For healthrelated claims, including weight-loss claims, an advertiser must demonstrate that it has
competent and reliable scientific evidence to support any claimed reasonable basis to
assert that the claims are true. FTC v. NPB Adver., Inc., No. 8:14-cv-115, 2016 U.S.
Dist. LEXIS 151840, at *4, *13 (M.D. Fla. Nov. 2, 2016). Additionally, the FTC’s expert,
Dr. Steven Heymsfield (“Dr. Heymsfield”), a medical doctor at the Pennington Biomedical
Research Center at Louisiana State University and an expert in obesity treatment and
weight loss, opined that no competent and reliable scientific evidence for Defendants’
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claims existed.

(Dkt. 210-3)

To prove a weight-loss claim, “experts in the field of

obesity treatment and weight loss would require well-designed and properly conducted
clinical trials.” (Dkt. 210-3 at 14) Dr. Heymsfield explained that a trial should be doubleblind and placebo-controlled so that the testers and participants are unaware of who is
assigned to a particular group. (Id.) Dr. Heymsfield also explained that a valid clinical
trial would have at least eighty participants and last at least three months. (Id. at 14–15)
He stated that a clinical trial should test the substance, not the individual ingredients, for
which the claims are made because it is well established in the scientific community that
the efficacy of individual ingredients is insufficient to establish the efficacy of those
ingredients combined. (Id. at 16)
In their response, Defendants argue that the randomized controlled test (“RCT”)
described by Dr. Heymsfield is not required to provide competent and reliable scientific
evidence. (Dkt. 221 at 18–22) Defendants’ contention is rooted, primarily, in United
States v. Bayer Corp., 2015 WL 5822595 (D.N.J. Sept. 24, 2015).

In Bayer, the

Government sought a contempt order against Bayer for violating a consent decree. Id.
at *2. The Government alleged that Bayer failed to provide an RCT as competent and
reliable scientific evidence to substantiate its advertising claims. Id. at *14. The court
noted the absence of a legal requirement for RCTs and concluded that the “four corners”
of the consent decree did not contain any language that required Bayer to provide RCTs
to substantiate the claims; ultimately, the court ruled that the Government failed to carry
its burden.

Id. at *3, 14–15.

However, the Bayer decision is inapposite both

procedurally and factually. Here, the moving party is not challenging a consent decree
such that it carries a legal burden to establish a violation by clear and convincing
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evidence.

Moreover, the FTC is not precluded from requiring RCTs or challenging

claims for lack of an RCT, and the absence of the RCT is just one piece of evidence
demonstrating the lack of competent and reliable evidence of the truth of the claims or
their reasonableness.
Defendants failed to produce any competent and reliable scientific evidence to
substantiate their claims. In September 2015, the same month that the FTC filed this
Complaint, Defendants’ products were studied by the Center for Applied Health Sciences,
which issued a report after a clinical trial on the Roca Labs products. (Dkt. 210-4 at 17)
Dr. Heymsfield reviewed the study, which Defendants provided to the FTC. (Id. at 8–9)
The study tested thirty-one overweight adults, including seventeen adults who used the
Roca Labs products for twenty-eight days. (Id. at 17) The results showed that the
participants did not lose weight after taking the Roca Labs products and that there was a
“slight but statistically insignificant ‘trend’ that active users reported feeling less hungry
three hours after taking the product.” (Id. at 18) He noted the study reflected that there
was no “lasting reduction in gastric capacity.” (Id.) Dr. Heymsfield determined that the
trial did not provide any competent or reliable scientific evidence because the trial design
was flawed. (Id.)
Additionally, Dr. Heymsfield opined that the scientific articles on weight loss and
individual dietary fibers, the specific articles posted on Roca Labs Websites, and other
materials provided by Roca Labs do not offer any competent and reliable scientific
evidence in support of Defendants’ claims. 2 (Dkt. 210-3 at 11–12) Defendants offer the

2

Defendants specifically highlight two research study articles, and both are sponsored by
Corporate Defendant MCO. (Dkts. 221-3, 221-4) One of the authors is Defendant Juravin, who
has not been identified as an expert, and the other three authors’ qualifications are not listed.
(Id.)
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affidavit of Dr. Marcus Free (“Dr. Free”), who is a board-certified surgeon and was recently
hired as medical director for MCO, as evidence that the Regimen “does appear to be
safer, more effective, and superior in several ways to currently available bariatric surgical
procedures.” (Dkt. 201-1 ¶¶ 6, 9–13) Defendants have not established that Dr. Free is
a pertinent professional or expert in the field of obesity treatment and weight loss. As
such, Dr. Free’s opinion cannot be used as a basis for competent reliable and scientific
evidence.
As it relates specifically to Count II, the FTC also has demonstrated that
Defendants’ claim that the use of Formula and Anti-Cravings is scientifically proven to
have a ninety-percent success rate in forcing users to eat half their usual food intake and
cause substantial weight loss is false.

This representation of success is an

establishment claim because the claim purports to be supported by scientific evidence.
By law, an establishment claim is required to have a certain level of scientific proof to
support of the claim. Thompson Med. Co., Inc. v. FTC, 791 F.2d 189, 194 (D.C. Cir.
1986) (explaining that an advertiser “must possess the level of proof claimed in the ad” to
support an establishment claim). The advertiser must have sufficient evidence to satisfy
the relevant scientific community of the claim’s truth. POM Wonderful, LLC v. FTC, 777
F.3d 478, 491 (D.C. Cir. 2015). Defendants have advertised the “scientifically proven”
claim online, but they have not produced any evidence to support the claim. (Dkt. 2 at
36) As discussed above, Defendants have failed to provide any evidence of a valid
clinical study on the Roca Labs products. Hence, the unsubstantiated claim is false and
likely to mislead consumers into believing that it was supported when it was not.
Transnet Wireless Corp., 506 F. Supp. 2d at 1266–67 (concluding that the express claims
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are presumptively material and inherently misleading); Thompson Med., 791 F.2d at 194
(affirming the FTC’s ruling that an unsubstantiated establishment claim was misleading).
As to Counts I and II, the FTC has established no competent or reliable scientific
evidence

substantiates

Defendants’

express

claims,

misrepresentations likely to mislead reasonable customers.
evidence to raise a dispute of fact.

which

are

material

Defendants offer no

Consequently, the FTC is entitled to summary

judgment on Counts I and II.
2.

Defendants’ Representations About Gastricbypass.me (Counts

IV, V)
The FTC is entitled to summary judgment on Counts IV and V. The FTC alleges
that Defendants deceived consumers by failing to disclose that the testimonials were
made by people who were compensated and that Defendants owned an informational
website. Specifically, the FTC alleges that Defendants failed to disclose the financial
incentives paid to or offered to people who provided testimonials for the Roca Labs
products and who posted positive comments on blogs and social media. (Dkt. 210 at
42) The FTC also contends that “Defendants misrepresented Gastricbypass.me as an
independent, objective resource for research and information related to bariatric surgery
and alternatives to bariatric surgery for weight loss, and about Roca Labs products.” (Id.)
The evidence to support the FTC’s allegations is undisputed.
Material misrepresentations or omissions on which a consumer would likely rely to
decide whether to make a purchase constitute deceptive advertising. Tashman, 318
F.3d at 1277. Juravin testified that he created Gastricbypass.me to “educate and scare
people about” gastric bypass surgery. (Dkt. 210-8 at 59, 174:9–177:4) Only Roca Labs
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products were discussed favorably on the site, although there was no disclosure of the
affiliation with Defendants. (Id. at 59, 175:15–17) Juravin stated that Gastricbypass.me
was controlled by Roca Labs and that he was responsible for the content, but he did not
see any value in letting consumers know “[h]ey we are Roca Labs.” (Id. at 59–60,
175:22–177:4)
Purportedly satisfied customers—“Carla” and “Roxie”—depicted in the videos
posted on RocaLabs.com were actually Defendants’ employees.

(Dkt. 210-19 at 8,

36:3–18; Dkt. 210-19 at 40, 193:11–194:10; Dkt. 210-19 at 33–34, 168:11–169:20; Dkt.
210-23 at 10, 39:20–24) Defendants directed their employees to create blogs or fictitious
posts. For example, Roca Labs General Manager Sharon King (“King”) testified that she
wrote a Roca Labs product review under the name of “Fran,” which was a fictitious name,
and that Juravin edited the review. (Dkt. 210-19 at 48, 238:24–239:23; Dkt. 210-19 at
48, 239:3–14) Juravin also directed King to instruct “the Customer Service people” to
write posts or reviews and comment on Roca Labs Facebook advertisements. (Dkt. 2108 at 69, 237:16–238:8, 238:16–17; Dkt. 210-8 at 72, 281:24–282:24; Dkt. 210-19 at 45,
226:15–227:8) Defendants did not instruct the employees to disclose their affiliation with
Defendants.

(Dkt. 210-19 at 45, 227:5–8)

Roca Labs employee Sharon Hensley

(“Hensley”), who appeared on video as “Roxie,” testified that she was asked to post
positive comments monthly on Facebook about Roca Labs monthly and did not state her
association with Defendants.

(Dkt. 210-23 at 19, 138:13–140:10; Dkt. 210-19 at 7,

27:20–24)
Defendants admit that Gastricbypass.me did not state its affiliation with RLI. (Dkt.
221 at 30) Yet, they argue that Roxie’s testimonial is valid because the weight loss
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occurred prior to her employment, although Roxie’s video was recorded after she was
employed by Defendants. (Dkt. 221 at 30–31; Dkt. 210-23 at 8, 30:9–18; Dkt. 210-23 at
8, 32:17–33:3)

Defendants’ argument misses the point.

The fact that Roxie

experienced weight loss success prior to her employment has no bearing on the fact that
Defendants failed to disclose their financial relationship with Roxie and others who gave
testimonials. As such, the FTC has established that Defendants failed to disclose that
they owned the website, provided reviews of their own products, or had a financial
relationship with those who provided testimonials. Thus, there is no genuine issue of
fact in dispute on this issue.
The

financial

relationship

with

the

testimonialists

and

ownership

of

Gastricbypass.me is material. Defendants exclusively marketed their products online
and used testimonials and the website to entice prospective buyers to purchase the Roca
Labs products.

(Dkt. 210-24) The financial relationship also is material because

Gastricbypass.me website and testimonials involve health matters, weight loss claims,
and other information important to the consumer in deciding whether to purchase Roca
Labs products. NPB Adver., Inc., No. 8:14-cv-115, 2016 U.S. Dist. LEXIS 151840, at
*13 (granting summary judgment in favor of the FTC after concluding, in part, that the
defendant failed to disclose that the testimonialists were compensated and a reasonable
consumer likely would rely on the testimonials).

The Court finds that the FTC has

demonstrated that Defendants made material misrepresentations and omitted material
facts upon which reasonable consumers and prospective customers would likely rely.
Thus, the FTC is entitled to summary judgment on Counts IV and V.
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3.

Defendants’ Privacy Claim (Count VI)

The FTC is entitled to summary judgment on Count VI because there is no genuine
issue of material fact regarding Defendants’ misrepresentation that they would keep
private health information confidential. Defendants do not rebut that they made the
express privacy promise, which is presumptively material. Kraft, 970 F.2d at 322.
Prospective customers who purchased Roca Labs products online entered their
health information through the “Qualify & Order” pages that included a Questionnaire,
also called a Health Application. The Qualify & Order page stated that the information
that prospective customers enter would be kept confidential and would not be shared.
(Dkt. 210-8 at 54, 156:1–157:3; Dkt. 210-14 at 75; Dkt. 210-19 at 17, 95:14–24) Prior to
submitting their order, prospective customers were required to enter their height, weight,
gender, age, and information regarding their health issues and weight-related
psychological issues on the Questionnaire or Health Application. (Dkt. 210-8 at 55,
157:23–159:24)
Despite a confidentiality promise, Defendants published customers’ sensitive
details and disclosed their personal information to payment processors. 3 In responding
to other customers’ disputes about credit card charges for Roca Labs products, RLI
stated, in part, that the customer had completed a “Qualification Form and provided
personal and medical information.” (Dkt. 6-7 at 13) (citation omitted) RLI disclosed
the personal information to payment processors, such as the height, weight, age, and sex
of the customers. (Id. at 13–14) RLI also disclosed the customers’ personal responses

3 The Court does not rely on the Defendants’ publication of sensitive information in court filings.
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regarding why they wanted to lose weight, such as “[b]ecause I want to feel good and
stop being sick and tired.” (Id.)
Defendants admit that customers’ information from the Questionnaire or Health
Application was included in communications with credit card payment processors. (Dkt.
221 at 33) Defendants argue that the information was publicly available and was
necessarily disclosed to address disputes with the credit card payment processors. (Id.
at 33–34) Defendants also contend that in 2014 the Terms and Conditions stated: “Your
information will not be shared or sold for as long as you do not breach the Terms and we
will have to use the information provided.” (Dkt. 210-10 at 3) These arguments are
without merit. Defendants offer no evidence that the customers’ current weight, desired
weight loss, and other health information was publicly available. Defendants also offer
no supporting evidence that disclosure of customers’ sensitive information was necessary
to respond to disputes regarding the credit card charges. Further, the 2014 Terms and
Conditions that Defendants cite is dated June 2014, and Alice King and the Broward
Customers purchased the products prior to the June 2014 version of the Terms and
Conditions. (Dkt. 210-10 at 2; Dkt. 6-5 at 44, 99-100, 103, 104)
In light of the disclosures, it is undisputed that Defendants’ express claims that
customers’ information would remain private were material and false. See 15 U.S.C. §
52(b) (providing that the dissemination of false advertisements constitutes an unfair or
deceptive practice under Section 5(a)). Thus, as to Count VI, the Court concludes that
there are no triable issues on this point and the FTC is entitled to summary judgment.
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4.

Defendants’ Discount Claim (Count VII)

The FTC is entitled to summary judgment on Count VII because Defendants’ postpackaging materials misrepresented that consumers had agreed to pay hundreds of
dollars more for the Roca Labs products than what they actually paid if they posted
negative reviews about the products or Defendants. Defendants do not dispute that they
made the discount claim or that it is material.

Instead, Defendants argue that the

discount claim is not deceptive because customers agreed to the discount and its
associated requirements.
When customers received the package of Roca Labs products, two documents
were included in the package. In the “Summary” of the Terms and Conditions and a
“Thanks for purchasing” packaging insert, customers were told they were given a
“discount off the unsubsidized price of $1580 in exchange for [their] agreement to promote
[Defendants’] products” and would owe the full price of $1,580 if they did not honor the
agreement. (Dkt. 210-14 at 84; Dkt. 58 ¶ 53; Dkt. 2-1 at 61–62; Dkt. 6-3 at 30)
Defendants argue that the discount claim is not deceptive because customers
were aware of and agreed to the discount and the non-disparagement clause prior to
purchase. They contend that customers were provided sufficient notice in the Terms and
Conditions prior to purchase and after the purchase in the documents shipped with the
products. (Dkt. 221 at 36–37) Defendants suggest that the prior notice in the Terms
and Conditions dispels the deception. These arguments fail for two reasons.
First, Defendants created an overall net impression that the price of the product
was $480 without reference to a discount or any concessions as to publishing negative
comments. Defendants advertised that the basic package of Roca Labs products costs
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$480 for purchasers with a “valid health insurance.” (Dkt. 6-2 at 64) In multiple online
advertisements, including those that appeared on Google, Bing, and Facebook,
Defendants advertised the cost as simply $480, at least for a basic package of Roca Labs
products.

(Dkt. 210-11, Dkt. 210-12; Dkt. 210-13)

At the top of the “Roca Labs

Procedure Cost” page of Defendants’ Websites, Defendants state “Only $480 and NO
surgery to gastric bypass cost of $8,000 + health insurance payments. Save yourself from
surgery that can cost your life. Save 90%.” (Dkt. 6-2 at 64) Farther down on that page,
in smaller print, Defendants state that the “Roca Labs Formula is available for as low as
$480” and display a chart showing the various packages, from the basic package for $480
to the customized package for $1,080. (Dkt. 6-2 at 64) The price differences in the
packages reflect the quantity of products ordered and the level of customer service
provided. (Id.) Several of the banner ads that appear online typically have five words:
“GASTRIC BYPASS NO SURGERY $480.”

(Dkt. 210-10)

Scores of search

advertisements also convey the price as $480, stating, for example, “Mini Gastric Bypass
$480” followed by “Official Site: No Surgery Solution! Reduce Stomach Size & Lose
Weight.”

(Dkt. 210-12 at 34–87, 93)

The advertisements did not contain any

disclaimers that the price was discounted or subsidized in exchange for a customer’s
agreement to refrain from publishing negative comments. As such, Defendants created
an overall net impression that the price was $480, with no exceptions or limitations.
Second, the disclaimer in the Terms and Conditions did not dispel the net
impression. Although the Terms and Conditions were disclosed on a hyperlinked page,
it was unlikely that consumers would have noticed or clicked on the link. The link to the
Terms and Conditions was at the bottom of the RocaLabs.com page, just above the
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“Submit” button.

(Dkt. 6-3 at 28)

Prior to purchasing the Roca Labs products,

customers were required to check a box next to the statement “I have checked and do
not have any medical reason that can prevent me from suing the Roca Labs Gastric
Bypass Alternative procedures and I have read and agree to the terms, privacy and
money back reward / return policy.” (Id.) However, customers were not required to read
the Terms and Conditions prior to purchasing. (Dkt. 221 at 37) For customers who may
have accessed the Terms and Conditions, the disclaimer about the discounted price and
non-disparagement clause was inconspicuous and buried among legal, contractual
language. (Dkt. 2-1at 10, 11, 23, 26, 48, 53)
Hence, the disclaimer in the Terms and Conditions fails to dispel the net
impression that the price was $480 with no strings attached. See FTC v. Commerce
Planet, Inc., 878 F. Supp. 2d 1048, 1065 (C.D. Cal. 2012) (holding that terms disclosed
in a separate, hyperlinked page is insufficient to overcome net impression that the auction
kit was free; stating that “disclosures do not automatically exonerate deceptive activities”),
aff'd in part and rev’d on other grounds, 815 F.3d 593 (9th Cir. 2016); Washington Data
Resources, 856 F. Supp. 2d at 1275 (concluding that a disclaimer buried in a contract
provided late in the purchase process is insufficient to dispel a deceptive net impression);
FTC v. Cyberspace.com LLC, 453 F.3d 1196, 1200 (9th Cir. 2006) (concluding that smallprint disclosure on back of a check was insufficient to defeat net impression that the check
was a rebate or refund). Defendants cannot avoid liability by exclusively advertising that
the product costs $480 without any caveats and then burying the conditions of the
discount in a separate disclaimer.
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Defendants’ misrepresentation is material and deceptive because it is an express
claim that involves important information to customers: the price of the product and
limitations on what customers could say about the products or Defendants. A customer
would likely be misled to believe that he or she had the option to purchase the product at
“full” price and maintain the ability to post negative but truthful comments. Customers
also would likely to be misled to believe that they had actually agreed to refrain from
posting negative comments, when they had not agreed to do so, by paying the purportedly
discounted price. 4 Accordingly, the Court finds that the FTC is entitled to summary
judgment as to Count VII.
B.

Defendants’ Gag Clause Practices (Count III)

The FTC alleges that Defendants’ practices related to the gag clause, which
prevents customers from making negative comments about Defendants or their products,
are unfair under Section 5 of the FTC Act. (Dkt. 210 at 45) In the response and their
own motion for partial summary judgment as to this count, Defendants contend that the
clause is not illegal and that the FTC cannot demonstrate that the practices are unfair.
(Dkt. 221; Dkt. 212) Defendants also argue that they lacked fair notice that the FTC
would interpret their practices as unfair. (Dkt. 221 at 29) For the reasons that follow,
the Court finds that the FTC is entitled to summary judgment on Count III.
1. Legality of the Gag Clause
Defendants argue that the FTC cannot assert that the gag clause was unfair
because it was part of a valid contract between Defendants and the customers. (Dkt.

4

In her declaration, customer LaShawn Baker stated that she “did not see or ready anything on
the Roca Labs website explaining that [she] was not allowed to talk badly about the product.”
(Dkt. 6-15 at 2) Other customers made similar statements in their declarations. (Dkt. 210-25–
210-31)
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212 at 11–14) Defendants contend that the gag clause was part of the Terms and
Conditions that customers agreed to because they were required to click on a box next
to a sentence stating, inter alia, that they had read and agreed to the terms before buying
the product. (Id. at 13) Defendants cite to a plethora of cases about the enforceability
of online “clickwrap” contracts. As Defendants concede, the enforceability of the contract
is not at issue or before the Court.

(Id. at 14)

The issue is whether Defendants’

practices related to the gag clause were unfair under Sections 5 of the FTC Act. Thus,
the Court finds no merit in Defendants’ contention that the FTC is unable to proceed
against Defendants on this basis.
2. Unfairness of the Gag Clause
Under Section 5 of the FTC Act, an act or practice is unfair if it “causes or is likely
to cause substantial injury to consumers which is not reasonably avoidable by consumers
themselves and not out weighed by countervailing benefits to consumers or to
competition.” 15 U.S.C. § 45(n). Additionally, the FTC “may consider established public
policies” in its determination of an unfair act or practice. Id.
a. Likely to Cause Substantial Injury
The FTC alleges that restricting the flow of information to consumers and the
marketplace causes or is likely to cause substantial injury. (Dkt. 210 at 44) To support
its claim, the FTC cites to the declaration and expert report of Dr. Paul Pavlou (“Dr.
Pavlou”), who is an associate dean and professor of information technology and strategy
at Temple University. (Dkt. 210-5). Dr. Pavlou stated that suppressing truthful negative
reviews negatively affects consumers and the marketplace. (Id. at 8) He opined that
the absence of such reviews inflates the perception of Defendants and the products and
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also prevents future customers from learning about potential problems. (Id. at 8, 12 )
Consequently, Dr. Pavlou stated, prospective customers are encouraged to buy products
that ultimately may not be desirous or appropriate. (Id. at 8) Without any, or even with
very few, negative reviews, it is likely that “[c]onsumers are more inclined to purchase
Roca Labs’ products due to their inflated perceptions of product quality, misled by the
manipulated absence of negative reviews that artificially inflate[s] their expectations of
product quality,” according to Dr. Pavlou. (Id. at 13) The FTC asserts that Juravin’s
testimony supports its claim. Juravin testified that he paid a company $40,000 to “make
the false comments not show up up front” because false comments “create the wrong
impression” and hurt Defendants’ sales by at least $40,000.

(Dkt. 210-8 at 29–31,

56:22–62:7)
The FTC also argues that Defendants’ threats to sue and filing of lawsuits caused
or were likely to cause substantial injury. Defendants threatened legal action against
customers who complained or said they would complain to the Better Business Bureau
or who said they had plans to post negative comments online. (Dkt. 216 at 11) For
example, customer Marie McGaha (“McGaha”) stated in a declaration that she saw no
negative online reviews prior to buying Roca Labs products.

(Dkt. 6-14 at 2)

“Compared to gastric bypass surgery, [i]t seemed like a good option.” (Id. at 2) She
bought the products; however, she asked for a refund because she did not like the texture
of the mixture and it made her sick. (Id. at 2–3) Defendants declined to give her a
refund. McGaha wrote a blog about her experience, and readers called the company to
complain. (Id. at 3) Then, she received a letter from Defendants’ counsel, who wrote:
Your statements are defamatory, you are committing tortious interference
with business and inducing harassment, you have breached your contract
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with Roca Labs, and you are violating the Federal Lanham Act.
Additionally, your actions amount to criminal extortion, which is defined as
follows: “The obtaining of property or money from another induced by
wrongful use of actual or threatened force, violence, or fear, or under color
of official right.” This is exactly what you are doing. If this posting is not
IMMEDIATELY removed, Roca Labs will have no choice but to file suit
against you. Roca Labs will also have no choice but to contact law
enforcement regarding the harassing phone calls and the extortion.
(Id. at 7–8) (emphasis in original) McGaha also received an email from Defendants
asking for her “SS or driving license” so that Defendants could file a police report
regarding her “Slander, Defamation and Extortion.” (Id. at 10) After the email and the
letter, McGaha’s blog was removed by WordPress, which was also threatened by
Defendants with a lawsuit about the blog posts, according to McGaha.

(Id. at 4)

Subsequently, McGaha stopped writing about the product and abated her pursuit of a
Better Business Bureau complaint because she “couldn’t afford to get sued.” (Id. at 5)
McGaha stated she never received a refund. Another customer, Amina Di’Leonardi
(“Di’Leonardi”), stated in a declaration that she was threatened with legal action after filing
a complaint with the Better Business Bureau following an unsuccessful pursuit of a $173
refund for her first installment payment on the nearly $500 purchase. (Dkt. 210-27 at 3–
4) After being contacted by Defendants’ attorney, Di’Leonardi withdrew her complaint
because she did not want to be sued. (Id. at 4) Joyce Agbetunsin (“Agbetunsin”), a
customer, stated that she was threatened with a lawsuit after telling a Roca Labs
customer service representative that she did not think the product was legitimate and that
she wanted a refund. (Dkt. 210-26 at 4) Agbetunsin filed a complaint with the Better
Business Bureau in June 2011, but “[w]hen they became aggressive and threatening, I
gave up. I already lost too much time and money dealing with the issue.” (Id. at 5)
Agbetunsin never received her $440 refund.
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Defendants contend that the FTC provided no evidence of tangible harm, either
economic or physical, and relies solely on intangible harm to make its claim. Their
contention is without merit. Defendants offer no factual or legal basis to support their
argument that the FTC is required to provide evidence of tangible harm. Defendants cite
to the FTC Act’s legislative history, which explained “[i]n most cases, substantial injury
would involve monetary or economic harm or unwarranted health and safety risks.
Emotional impact and more subjective types of harm alone are not intended to make an
injury unfair.” S. Rep. No. 103-130, at 13, 1993 WL 322671 (1993). But neither the
legislative history nor the current law requires proof of tangible harm to the exclusion of
intangible harm, as Defendants assert. Further, the FTC is not required to prove that an
actual harm has occurred because “the FTC Act contemplates the possibility that conduct
can be unfair before actual injury occurs.” FTC v. Wyndham Worldwide Corp., 799 F.3d
236, 264 (3d Cir. 2015).
Because Defendants admittedly suppressed negative information about the
products and because Dr. Pavlou testified that the absence of negative information could
make a consumer more inclined to purchase Roca Labs products, the Court finds that
Defendants’ practices have caused or were likely to cause substantial injury to
consumers. The record demonstrates that some consumers paid hundreds of dollars for
the Roca Labs products and unsuccessfully sought refunds because of Defendants’
practice of issuing threats under the guise of enforcing the gag clause. Thus, the Court
finds that there is no genuine issue of fact on this basis that would preclude summary
judgment in favor of the FTC.
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b. Not Reasonably Avoidable by Consumers
The FTC contends that Defendants’ practices related to the gag clause cause were
likely to cause injury that was not reasonably avoidable because prospective customers
who search for information about Roca Labs products would not necessarily be made
aware of previous buyers’ negative but truthful experiences.

(Dkt. 210 at 48)

For

example, in her declaration, customer Rolisa Harper (“Harper”) stated that, after watching
YouTube videos, she was interested in the products.

(Dkt. 210-32 at 2–3)

She

“researched further and didn’t find any negative reviews for the product. This influenced
my decision to purchase the product. I always look at product reviews before I purchase
a product, especially when a product costs several hundred dollars.”

(Id. at 3)

Ultimately, without any or very little access to consumers’ negative experiences,
prospective buyers like Harper are prohibited from making an informed choice.
Defendants offer no evidence that their practices did not prohibit the availability of
negative reviews or that their practices were reasonably avoidable by the prospective
consumer.

Rather, Defendants argue that prospective customers could have

reasonably avoided any injury by reading the contract that contained the gag clause or
joining another weight loss program.

(Dkt. 212 at 17–18)

Defendants’ argument

misses the mark. Under this prong of the FTC Act, the FTC alleges that Defendants’
practices relating to the gag clause, not the gag clause itself, were unfair. Further,
because Defendants offer no facts to support a claim that prospective customers could
reasonably avoid a dearth of negative reviews, which the Defendants assiduously
prevented from being available, there is no genuine issue of a material fact in dispute on
this issue.
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c. Countervailing Benefits to Consumers or Competition
The FTC contends that there is no countervailing benefit to competition or
consumers that outweighs the injury caused or likely to be caused by Defendants’ gag
clause practices. (Dkt. 210 at 49) As discussed, the FTC has presented evidence that
consumers were injured or likely to be injured by the absence of negative reviews.
Defendants present no evidence to the contrary, only arguing that the practices benefited
consumers or competition and that a cost-benefits analysis is required.
Defendants assert that consumers benefited from the products by losing weight,
increasing their confidence, and taking steps toward a healthier lifestyle. (Dkt. 212 at
18) Defendants also argue that the FTC has provided no cost-benefit analysis, which
they assert is required by 15 U.S.C. § 45(n). (Dkt. 221 at 28)

Specifically, Defendants

contend that the statute requires courts to
compare (1) the sum of (a) the costs to Defendants of false negative reviews
and (b) the additional costs associated with Defendants’ compliance with
any order forbidding the disparagement clause going forward (collectively,
the “Relevant Costs”), with (2) the magnitude of any substantial consumer
injury caused or likely to be caused by the disparagement clause and the
attempts to enforce same (the “Relevant Benefits”).
(Dkt. 221 at 28–29)
Their arguments fail two primary reasons. First, Defendants’ recitation of the
benefits they claim consumers received from using the products ignores the issue
presented in this claim, which is whether Defendants’ gag clause practices, not their
products and services, presented a countervailing benefit.

Second, the Court is

unpersuaded that such a quantitatively precise cost-benefits analysis is required. The
statute, 15 U.S.C. § 45(n), does not provide for such a detailed analysis. The case cited
by Defendants to support their contention that a detailed cost-benefit analysis is required
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is inapposite. In Wyndham Worldwide Corp., the court noted that 15 U.S.C. § 45(n)
suggests that a cost-benefit analysis is a relevant inquiry in the context of analyzing
whether the defendant had fair notice of the FTC’s interpretation of a statute but went on
to say that such an inquiry considers several relevant factors. 799 F.3d at 255–56 (citing
Pa. Funeral Dirs. Ass’n, Inc. v. FTC, 41 F.3d 81, 91 (3d Cir. 1994) (stating that
“quantitative data is not necessary in such an evaluation” of whether the benefits of
banning casket handling fees outweigh the cost and the absence of quantitative data is
not fatal to the FTC’s analysis.)). The Wyndham court did not review a cost-benefits
analysis, as no such analysis was presented, no argument was made for an analysis to
be provided to the court, and the defendant’s fair notice claim was rejected on other
grounds.
Based on the evidence presented by the FTC, the Court finds that the FTC has
met its burden to establish that Defendants’ practices related to the gag clause were
unfair.

Only the FTC is entitled to summary judgment on this claim; Defendants’

amended motion for partial summary judgment as to Count III is due to be denied.
3. Fair Notice of the FTC’s Interpretation
Defendants argue that the FTC’s unfairness claim is barred by the fair notice
doctrine. (Dkt. 221 at 29) The fair notice doctrine prevents “deference [to the regulator]
from validating the application of a regulation that fails to give fair warning of the conduct
it prohibits or requires.” Global Green, Inc. v. S.E.C., 631 F. App’x 868, 870 (11th Cir.
2015) 5 (citing Gates & Fox Co. v. OSHRC, 790 F.2d 154, 156 (D.C.Cir.1986)).

5

The Court notes that “[a]lthough an unpublished opinion is not binding on this court, it is
persuasive authority. See 11th Cir. R. 36-2.” United States v. Futrell, 209 F.3d 1286, 1289
(11th Cir. 2000).
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However, this doctrine is only applied in very limited circumstances. Global Green, 631
F. App’x at 870 (citing Suburban Air Freight, Inc. v. Transp. Sec. Admin., 716 F.3d 679,
684 (D.C.Cir.2013)).

For example, the doctrine has been applied where the FCC

changed course regarding its interpretation of statutory provision and failed to provide fair
notice to two broadcasters. FCC v. Fox TV Stations, Inc., 567 U.S. 239, 253–58 (2012).
Defendants assert that they did not have fair notice that the FTC “would adopt
these interpretations in this case.” (Dkt. 221 at 29) Specifically, Defendants state they
had no knowledge that the FTC would consider that an intangible injury could constitute
a substantial injury under the statute. (Id. at 30) Defendants argue that neither the
FTC’s policy statements nor any FTC commissioner’s testimony provided them with
“ascertainable certainty” that an intangible harm would constitute a substantial injury.
(Dkt. 221 at 25–27) These arguments are unpersuasive.
In FTC Policy Statement on Unfairness, the FTC stated that:
the injury must be substantial. The Commission is not concerned with
trivial or merely speculative harms. In most cases a substantial injury
involves monetary harm, as when sellers coerce consumers into purchasing
unwanted goods or services or when consumers buy defective goods or
services on credit but are unable to assert against the creditor claims or
defenses arising from the transaction. Unwarranted health and safety risks
may also support a finding of unfairness. Emotional impact and other more
subjective types of harm, on the other hand, will not ordinarily make a
practice unfair.
FTC’s Policy Statement on Unfairness, Sen. Comm. on Commerce, Science and
Transportation (Dec. 17, 1980), appended to In the Matter of Int’l Harvester Co., 104
F.T.C. 949 (1984). The Unfairness Statement further clarified that an “injury may be
sufficiently substantial, however, if it does a small harm to a large number of people, or if

34

Case 8:15-cv-02231-MSS-CPT Document 234 Filed 09/14/18 Page 35 of 42 PageID 10989

it raises a significant risk of concrete harm.” Id. at p.5, n.12

The Policy Statement and

supplemental explanation harmoniously characterize substantial injury. Further, neither
states that intangible injury is excluded from the definition of substantial injury.
Defendants offer no evidence that the FTC abruptly changed course in its enforcement
guidelines or in its statutory provisions.

Accordingly, the Court rejects Defendants’

argument that the FTC’s claim is prohibited under the fair notice doctrine.
C.

Remedies

Under Section 13(b) of the FTC Act, the FTC seeks permanent injunctive relief
against Defendants and monetary relief against Juravin and the Corporate Defendants.
15 U.S.C. § 53(b). The Court finds that a permanent injunction against all Defendants is
warranted. 6
A permanent injunction is appropriate when there is a “cognizable danger of
recurrent violation.” Washington Data Resources, 856 F. Supp. 2d at 1282 (citing United
States v. W. T. Grant Co., 345 U.S. 629, 633 (1953)). Juravin testified that he has moved
away from using the Roca Labs brand and is now using “gastric.care,” but “[t]he formula
is the same formula.” (Dkt. 210-8 at 75, 367:7–368:2, 386:19–387:7) Juravin also
stated that he is marketing the products on Facebook, a “Lost 100” Website, and online
videos and chat. (Dkt. 210-16 at 31, 574:12–575:21) In his deposition, Juravin also

6

Defendants assert that they have complied with the preliminary injunction and, consequently,
the Court lacks subject matter jurisdiction. (Dkt. 221 at 45–47) The Court rejects their
argument. Defendants assert no factual basis to suggest that they have fully complied with the
injunction or that full compliance divests the Court of jurisdiction. The Court also is unpersuaded
by Defendants’ citation to FTC v. Shire ViroPharma Inc., CV 17-131-RGA, 2018 WL 1401329, at
*1 (D. Del. Mar. 20, 2018), appeal docketed No. 18-1807 (3d Cir. Apr. 11, 2018). In Shire, the
Court dismissed the FTC’s complaint after finding, in relevant part, that the FTC had not
adequately pled that the defendant was “about to violate” the law “when the alleged misconduct
ceased almost five years before filing of the complaint.” Id. at *6. The court did not find that it
lacked subject matter jurisdiction.
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said he told his Facebook boot camp customers: “I’m allowed to tell you anything I want;
to do anything I want with you that would lead you to a healthy weight . . .” (Dkt. 210-16
at 24, 542:1–17) He also testified that he will show the customers “any images I want.
I will do anything I want for them for as long as I lead them to achieve a healthy weight.”
(Id.)

Based on Defendants’ extended history of deceptive and unfair practices and

Defendants’ continued promotion of their products and comparisons to gastric bypass
surgery, the FTC has proven that a cognizable danger of recurrent violation exists. Thus,
a permanent injunction prohibiting Defendants’ deceptive and unfair practices is justified.
Because the Court has found Defendants liable for violating Section 5 of the FTC
Act, it also finds the FTC is entitled to monetary relief under Section 13(b) for consumer
redress, including disgorgement. As to the formula for calculating damages, in accord
with Eleventh Circuit precedent, FTC contends that the “proper measure of disgorgement
is the amount of the defendants’ unjust gains.” (Dkt. 210 at 53) The “amount of net
revenue (gross receipts minus refunds) . . . is the correct measure of unjust gains under
section 13(b).” Washington Data, 704 F.3d at 1327.
In contrast, Defendants invite the Court to calculate disgorgement by:
. . . tak[ing]the number of complaints registered with the Better Business
Bureau that are based on the customer’s assertion that the product did not
work as advertised from March of 2011 (the time of the first complaint
lodged with the BBB) to the date of this filing, September 29, 2018. That
number should then be multiplied by $350, the average selling price of the
Roca Labs Product during this time period. Finally, that number should be
multiplied by twenty-five (25) to account for customers that might feel the
product did not work as advertised, but who did not register a complaint with
the BBB.
(Dkt. 221 at 45) Defendants contend this calculation ensures that the disgorgement is
“based on the customer’s assertion that the product did not work as advertised.” (Id.)

36

Case 8:15-cv-02231-MSS-CPT Document 234 Filed 09/14/18 Page 37 of 42 PageID 10991

The Court declines Defendants’ invitation. This calculation is not in accord with
binding precedent.

The Eleventh Circuit has held that the proper measure of

disgorgement is unjust gain, not consumer loss, and the appropriate measure for unjust
gains is net revenue. Washington Data, 704 F.3d at 1326. Therefore, the Court finds
that the amount of damages in this action shall be calculated by the amount of gross sales
revenue minus the amount of customer refunds returned to consumers.
The FTC asserts the net revenue amount is $25,246,000—totaling the gross sales
revenue generated from sales minus what the FTC contends is a “reasonable
approximation” of customer refunds. (Dkt. 210 at 54) The Court notes that FTC has
provided sufficient evidence as to the amount of gross sales revenues, which totaled
$26.6 million during the relevant time period. (See e.g., Dkt. 210 at 54-24 at 1, 4).
Specifically the FTC provided Defendants’ corporate tax returns for 2011-2015, as well
as affidavit testimony verifying the reported revenue. (Id.; Dkt. 210, 54-9 at 153:1-154:6,
154:19-24, 167:2-168:9, 170:18-171:3, 176:22-177:15).

However, regarding the

$1,354,000.00 customer refund amount ($26,000,000.00 gross sales - $25,246,000.00
net revenue = $1,354,000.00), FTC merely states that the amount is a “reasonable
approximation.” It does not cite to record evidence, such as internal business records or
tax records or bank records. It offers no affidavit attesting to the specific amount of
refunds or how that approximation was derived. This Court has scoured the record and
cannot find any evidentiary support.
“The FTC bears the burden to show the ‘reasonably approximate’ amount of the
defendant's unjust gain.” Washington Data, 856 F. Supp. 2d 1247, 1281 (M.D. Fla.
2012).

In Washington, the FTC “establishe[d] a ‘reasonable approximation’ of net
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revenue” through affidavit testimony which explained how consumer sales data, including
refund data, was extracted from Defendants’ database and subsequently processed,
filtered, and analyzed. In addition, documentation was provided demonstrating FTC’s
calculations of the extracted consumer sales data which supported the unjust gains
approximation amount. Similarly, in FTC v. Partners in Health Care Ass’n, 189 F. Supp.
3d 1356, 1370 (S.D. Fla. 2016), the Court was provided with sufficient numerical evidence
to conclude that the FTC’s approximation of unjust gains was reasonable. 7

Here there

is no evidentiary basis to support the approximation amount provided by FTC is
reasonable.

Thus, the Court cannot make a determination at this time as to the

appropriate disgorgement amount until the parties have supplemented the record.
The Court also finds that both Juravin and Whiting are individually liable for the
Corporate Defendants’ deceptive and unfair acts. For the FTC to demonstrate that the
individuals are liable for the deceptive acts of a corporate defendant, the FTC must first
demonstrate that the business entities operated in an integrated manner, or as a common
enterprise. Washington Data Resources, 856 F. Supp. 2d at 1271. The factors used in
determining whether a common enterprise exists is whether the businesses “1) maintain
officers and employees in common, (2) operate under common control, (3) share offices,
(4) commingle funds, and (5) share advertising and marketing.” Id. at 1271 (citations
omitted).

Juravin and Whiting were the only owners and officers of the Corporate

Defendants. (Dkt. 210-24 at 6; Dkt. 219 ¶¶ 1–5) Juravin owns MCO and JI and has

7

Specifically, a Certified Fraud Examiner (CFE) went through Defendants’ files to estimate the
amount of loss, and then, using specialized software, the CFE executed a Transactions by
Enrollment Agent Report. From this report, the CFE was able to conclude that the corporate
defendants and their affiliates made $9,738,588.86 in gross sales and recorded $992,494.68 in
consumer refunds.
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been an officer of RLI and RLNU, and Whiting owns and has been an officer of RLI,
RLNU, and ZCL. (Dkt. 219) The entities also have comingled funds. For example,
revenues generated by MCO in 2014 and 2015 were reported on RLI’s corporate tax
returns. (Dkt. 210-8 at 29, 65:12–67:19; Dkt.210-24) In 2014 and 2015, JI’s income
was generated from either RLI, RLNU, or MCO. (Dkt. 210-16 at 18–19, 473:17–478:15)
Accordingly, the FTC has demonstrated that the Corporate Defendants operated as a
common enterprise.
Next, the FTC must establish that Juravin and Whiting knew of the deceptive acts
and either participated directly in or had authority or control over the acts. FTC v. Gem
Merch. Corp., 87 F.3d 466, 470 (11th Cir. 1996) (citing FTC v. Amy Travel Service, Inc.,
875 F.2d 564, 573 (7th Cir. 1989)). The FTC may demonstrate that the individuals had
“actual knowledge of material misrepresentations, reckless indifference to the truth or
falsity of such misrepresentations, or an awareness of a high probability of fraud along
with an intentional avoidance of the truth.”
omitted).

Amy Travel, 875 F.2d at 574 (citation

The FTC is not required to prove intent to defraud.

Id.

The FTC may

establish that an individual exercised control over the alleged deceptive practices with
evidence that the individual controlled the daily operations. Id. at 573. Also, the “degree
of participation in business affairs is probative of knowledge.” Id. (citation omitted).
The FTC has established that Juravin knew of the material misrepresentations and
either participated in the deceptive acts or had authority to control them. Juravin testified
that anything that was on the site was his responsibility. (Dkt. 210-8 at 50, 137:5–23)
Juravin controlled virtually every aspect of the Corporate Defendants’ business, including
marketing, websites, claim substantiation, expenditures, personnel, and lawsuits. (Dkt.
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210-16 at 7, 426:5-432:3). Juravin also stated that he was in charge of daily operations
and was “responsible for all matters involving Roca Labs, including advertisements.”
(Dkt. 210-24 at 8) From 2009 through 2015, Juravin controlled RLI, personally receiving
approximately $7 million from the Corporate Defendants during this timeframe. (Dkt.
210-16 at 11, 448:9-450:2) Juravin solely controlled RLI’s main checking accounts,
personally authorized credit card expenditures for online ads, and received bank
statements addressed to his home for RLI and ZCL. (Dkt. 210-16 at 14, 458:5-460:7;
Dkt. 210-18 at 38, 221:7-222:25). Juravin also liberally transferred funds back and forth
between all Corporate Defendants, transferred substantial sums to himself, and often paid
his personal expenses from the corporate accounts. (Dkt. 210-18 at 43, 240:9-242:20;
Dkt. 210-18 at 45, 249:1-252:15; Dkt. 210-18 at 49, 266:1-267:19)
The FTC also has established that Whiting had knowledge of the deceptive acts.
Whiting testified that he was aware of customers’ complaints and lawsuits filed by
Defendants.

(Dkt. 210-18 at 17, 74:4–9; 76:6–19)

Thus, Whiting cannot disavow

knowledge of Defendants’ practices. The FTC also has demonstrated that Whiting had
authority to control the deceptive acts because he was an owner and officer of RLI, ZCL,
and RLNU.

Whiting testified that he performed bookkeeping and tax preparation

services for some, if not all of the Corporate Defendants. (Dkt. 210-18 at 11, 63:19–
72:16. Whiting’s portrait appeared on the Roca Labs Website indicating that he was
president of the company.

(Dkt. 210-18 at 52, 281:4–282:5)

Whiting also was

compensated for his services, receiving $42,000 in director’s fees one year. (Dkt. 21018 at 11, 49:3–20) Whiting’s role appears to be more limited than Juravin’s role, though
Juravin made Whiting aware of matters that required RLI corporate approval. (Dkt. 210-
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8 at 21, 19:14-20:4) Whiting testified that he and Juravin discussed advertising, but only
as to “how the advertising money was going to be spent.” (Dkt. 210-18 at 10, 46:4–11)
Nevertheless, the FTC has established that Whiting is liable for injunctive relief due to
Whiting’s knowledge of the deceptive practices and authority over the acts as a corporate
owner and officer.
IV.

CONCLUSION
Upon consideration of the foregoing, it is hereby ORDERED that:
1. Defendants’ [Amended] Motion for Partial Summary Judgment as to Count
Three of the Amended Complaint (Dkt. 212) is DENIED.
2. Plaintiff’s Amended Motion for Summary Judgment (Dkt. 210) is GRANTED as
to liability but TAKEN UNDER ADVISEMENT as to damages.
3. For the reasons stated above, the Court is unable to evaluate Plaintiff’s
“reasonable approximation” of the disgorgement amount. Thus, the Plaintiff is
required to supplement the record as follows:
a. Within twenty-one (21) days of the date of this Order, Plaintiff is
directed to file a supplemental memorandum of no more than five pages
that sets forth the specific refunds that are included in its approximation
of the disgorgement amount. Plaintiff shall also attach relevant
documents of record and deposition testimony, if any, that support this
amount. No additional discovery is permitted.
b. Upon Plaintiff’s submission of this documentation, the Defendants shall
have fourteen (14) days to respond.
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4. The Clerk is directed to ADMINISTRATIVELY CLOSE this case pending the
supplementation and documentation of the disgorgement amount and briefing
by the Parties.
DONE and ORDERED in Tampa, Florida, this 14th day of September, 2018.

Copies furnished to:
Counsel of Record
Any Unrepresented Person
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